Compare Saptak Chem & with Similar Stocks
Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at 0 times
Negative results in Dec 25
Risky - Negative EBITDA
Stock DNA
Trading & Distributors
INR 5 Cr (Micro Cap)
235.00
21
0.00%
-1.05
-0.43%
-2.06
Total Returns (Price + Dividend) 
Saptak Chem & for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Saptak Chem & Business Ltd Downgraded to Strong Sell Amid Mixed Technicals and Weak Financials
Saptak Chem & Business Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating downgraded from Sell to Strong Sell as of 12 Mar 2026. This shift reflects a complex interplay of deteriorating financial performance, cautious valuation metrics, and nuanced technical indicators, despite the company’s impressive long-term returns. Investors are advised to carefully consider these factors amid the stock’s volatile price movements and sector dynamics.
Read full news article
Saptak Chem & Business Ltd Upgraded to Sell on Technical Improvements Despite Financial Challenges
Saptak Chem & Business Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 10 March 2026, driven primarily by improvements in its technical indicators despite ongoing financial challenges. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change, providing investors with a comprehensive understanding of the stock’s current standing and outlook.
Read full news article
Saptak Chem & Business Ltd Downgraded to Strong Sell Amid Mixed Technicals and Weak Financials
Saptak Chem & Business Ltd, a player in the Trading & Distributors sector, has seen its investment rating downgraded from Sell to Strong Sell as of 2 March 2026. This shift reflects a complex interplay of deteriorating financial performance, cautious valuation metrics, and mixed technical signals, despite the company’s impressive long-term price returns. Investors are urged to carefully consider these factors amid the stock’s volatile recent price action.
Read full news article Announcements 
Closure of Trading Window
23-Mar-2026 | Source : BSEClosure of Trading Window
Announcement under Regulation 30 (LODR)-Resignation of Director
17-Mar-2026 | Source : BSEResignation of Director
Board Meeting Outcome for As Attached
17-Mar-2026 | Source : BSEAs attached
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Alpha Antibiotics Limited (12.58%)
Saptak Chem (24.13%)
55.74%
Quarterly Results Snapshot (Standalone) - Dec'25 - YoY
YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024
YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024






